Sunesis Pharmaceuticals (SNSS) Misses Q2 EPS by 2c

Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q2 EPS of ($0.12), $0.02 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $610 thousand versus the consensus estimate of $1.03 million.

For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Prenetics Global (PRE) Tops Q2 EPS by 18c
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business